MedTrace Logo

CKD-828 Telmisartan Non-Responder Trial

NCT01426100 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 183

Last updated 2012-09-13

No results posted yet for this study

Summary

The aim of the present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (40/2.5mg and 40/5mg) compared with telmisartan monotherapy (80mg) in hypertensive patients inadequately controlled by telmisartan monotherapy.

Conditions

Interventions

DRUG

CKD-828 40/2.5mg

Fixed dose combination of Telmisartan 40mg and S-Amlodipine 2.5mg

DRUG

CKD-828 40/5mg

Fixed dose combination of Telmisartan 40mg and S-Amlidioine 5mg

DRUG

Telmisartan 80mg

Telmisartan 80mg monotherapy

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2012-05-31
Completion
2012-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01426100 on ClinicalTrials.gov